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To the Editor: Resistance to β-lactam antibiotics in Enterobacteriaceae 
has steadily increased, with the emergence of carbapenem-resistant 
Enterobacteriaceae (CRE) seen in the past decade. Resistance to 
carbapenems may be mediated via a variety of mechanisms, but 
the development and spread of carbapenemases (β-lactamase 
enzymes that hydrolyse carbapenems and many other β-lactam 
antibiotics) in Enterobacteriaceae has caused global concern. One 
such carbapenemase, NDM-1 (New Delhi metallo-β-lactamase), first 
described in 2009,1 has rapidly emerged as the leading threat to the 
treatment of infections caused by Enterobacteriaceae. 
A Swedish patient of Indian origin, who travelled to New Delhi 
in 2007, developed an infection caused by a strain of Klebsiella 
pneumoniae harbouring the blaNDM-1 gene encoding NDM-1. A 
subsequent study demonstrated that NDM-1-positive isolates were 
already present in Indian hospitals in 2006.2 Dissemination of NDM-1- 
positive bacteria in the environment and community-acquired infection 
with these resistant organisms in parts of India is well-documented.3,4 
Enterobacteriaceae with NDM-1 have since been isolated from patients 
in the USA, Canada, UK, Europe, Australia, Oman, Japan, Singapore and 
Africa.5-7 The presence of NDM-1 was demonstrated in certain multi-
drug resistant (MDR) K. pneumoniae isolates from a Kenyan hospital, in 
strains archived over a 3-year period (2007 - 2009).5
The blaNDM-1 gene has been found on conjugative plasmids, which 
are mobile genetic elements.4 This facilitates transfer of the gene 
between bacteria, resulting in the emergence of resistance in other 
unrelated genera, such as Acinetobacter and Vibrio.3,8 NDM-1- 
positive bacteria often carry genes that confer resistance to other 
non-β-lactam antibiotics, like the fluoroquinolones, sulphonamides 
and aminoglycosides.4,7 Of additional concern is that resistance to 
tigecycline and colistin has been described, further limiting available 
treatment options.4,7 We report the first laboratory-confirmed case of 
an NDM-1-producing isolate from South Africa.
Methods and results 
Case report
A 63-year-old black man presented to the Charlotte Maxeke 
Johannesburg Academic Hospital, with a 2-month history of a 
productive cough, right-sided pleuritic chest pain, dyspnoea, fever, 
and weight loss. The patient had previously been well, but had 
recently been diagnosed with HIV (not started on antiretroviral 
treatment) and hypertension. He had 2 previous admissions to the 
same hospital in 2010, for a trauma-related injury and a diarrhoeal 
illness, respectively. No immediate family members sought healthcare 
in the recent preceding years. The patient’s house was noted to have 
proper sanitation with running water. He was a truck driver by 
occupation and travelled primarily within South Africa, but had also 
recently travelled to Mozambique and Zambia.
The patient appeared wasted with generalised lymphadenopathy and 
mild conjunctival pallor. He was apyrexial and normotensive. There were 
no chest scars or deformities, and he had clinical evidence of a pneumonic 
process in the right middle lobe. A chest X-ray (CXR) revealed an area of 
opacification in the right middle lobe, with an air-fluid level suggestive of 
either a complex pleural collection or a lung abscess. 
The patient was started on a course of intravenous amoxicillin-
clavulanate and oral azithromycin; treatment was changed after 5 
days to oral ciprofloxacin (750 mg twice daily), after a carbapenem-
resistant Enterobacter cloacae was isolated from sputum cultures 
(refer to ‘Laboratory testing’). Fluid collection was achieved with a 
pig-tail catheter under ultrasound guidance. Macroscopically, the 
collection appeared empyematous; the biochemistry was consistent 
with this observation. A total of 150 ml of fluid was drained over 
3 days; the catheter was removed following complete resolution 
confirmed on CXR. The fluid was culture-negative and investigations 
eliminated the possibility of tuberculosis. The patient received HIV-
counselling, was initiated on antiretroviral treatment, and discharged 
with follow-up scheduled at the outpatient clinic after 2 weeks.
At the follow-up visit, the patient appeared to have recovered well. 
On re-culture of his sputum, an extended spectrum β-lactamase 
(ESBL)-producing K. pneumoniae was isolated. No CRE were isolated 
with a screening rectal swab. The CXR showed complete resolution.
NDM-1 has arrived: First report of a carbapenem resistance 
mechanism in South Africa
W Lowman, C Sriruttan, T Nana, N Bosman, A Duse, J Venturas, C Clay, J Coetzee
The New Delhi Metallo-β-lactamase (NDM) resistance mechanism 
in Enterobacteriaceae threatens to render serious Gram-negative 
infections untreatable. The NDM-1 enzyme hydrolyses all available 
penicillin, cephalosporin and carbapenem antibiotics, and is 
commonly accompanied by additional resistance mechanisms 
to multiple antibiotic classes. Initially identified as a significant 
healthcare risk on the Indian sub-continent, it has rapidly become 
a global problem, posing significant diagnostic and management 
challenges. Here we report the first laboratory-confirmed case of 
NDM-1 in South Africa.
S Afr Med J 2011;101:873-875.
Department of Clinical Microbiology and Infectious Diseases, School of Pathology 
of the National Health Laboratory Services and University of the Witwatersrand, 
Johannesburg
W Lowman, MB BCh, MMed (Microbiol), FCPath (SA) (Microbiol)
C Sriruttan, MB BCh, DTM&H, FCPath (SA) (Microbiol)
T Nana, MB BCh, DTM&H, FCPath (SA) (Microbiol)
N Bosman, MB BCh, DTM&H, FCPath (SA) (Microbiol)
A Duse, MB BCh, DTM&H, MSc (Med), MMed (Microbiol), FCPath (Microbiol) 
(SA)
Department of Internal Medicine, Charlotte Maxeke Johannesburg Academic 
Hospital, University of the Witwatersrand, Johannesburg
J Venturas, MB ChB, FCP (SA), Cert Pulmonology, Cert Critical Care
Department of Clinical Microbiology and Molecular Biology, National Referral 
Laboratory, Ampath National Laboratory Services, Centurion
C Clay, PhD
J Coetzee, MB ChB, FCPath (SA) (Microbiol) 
Corresponding author: W Lowman (warren.lowman@wits.ac.za)
Scientific Letter
874
Scientific Letter
December 2011, Vol. 101, No. 12  SAMJ
Laboratory testing
The E. cloacae isolated from the sputum was identified with a 
MicroScan Walkaway system (Siemens Healthcare Diagnostics, USA). 
To verify the initial result, additional antimicrobial susceptibility 
testing (AST) was performed for a variety of antimicrobial agents, 
including a combination of broth microdilution and Etest (bioMérieux 
Clinical Diagnostics, France) (Table I). With the exception of 
tigecycline, colistin and fosfomycin, all minimum inhibitory 
concentrations (MICs) were interpreted using the Clinical and 
Laboratory Standards Institute (CLSI) breakpoints.9 The presence of 
a carbapenemase was presumptively confirmed using a combination 
of phenotypic methods. Using the method described by Zarfel et al.,11 
the isolate was genotypically analysed using specific primers (Inqaba 
Biotec, Pretoria) designed to detect the presence of the blaNDM-1 gene 
conferring carbapenem resistance. K. pneumoniae strain BAA-2146 
(ATCC, Manassas, USA), harbouring the blaNDM-1 gene, was used as 
a positive control.
Discussion
The emergence of NDM-1 in Enterobacteriaceae has heightened 
global concern regarding antimicrobial resistance. The MDR nature, 
propensity for horizontal transfer, and rapidity of global spread and 
emergence of micro-organisms harbouring this gene means that the 
threat of untreatable infections has arrived. To our knowledge, this is 
the first laboratory-confirmed case of an NDM-1-producing isolate 
in South Africa.
The implications of this are multifactorial, affecting the laboratory 
and the bedside. Treatment options are limited, with colistin and 
tigecycline currently the only feasible choices. Susceptibility to 
these agents is not guaranteed and numerous clinical issues relate 
to their use in treating severe MDR Gram-negative infections. A 
dearth of pharmaco-kinetic and -dynamic data on the use of colistin 
compromises optimal dosing; literature suggests that it should be used 
in combination with other agents such as rifampicin.12 Tigecycline, 
a broad-spectrum minocycline analogue, has a high volume of 
distribution with low serum levels, raising concern as to its efficacy 
in the treatment of bacteraemic patients. Furthermore, Pseudomonas 
aeruginosa and several Enterobacteriaceae are inherently resistant 
to this agent. The efficacy of these agents in the treatment of severe 
infections caused by the described isolates remains to be determined.
Early identification of NDM-1-producing Enterobacteriaceae 
(NPE), and timely infection prevention and control intervention 
is imperative to limiting further emergence and spread of these 
micro-organisms.13 Measures to ensure early laboratory detection 
of CRE are crucial in alerting clinicians and infection control staff 
to a potential carbapenemase producer. Clinicians must be made 
Table I. Susceptibility of isolate to various antibiotics as determined by different AST methods
MIC / susceptibility
MicroScan Interpretation Etest Interpretation BMD Interpretation
Antimicrobial agents (µg/ml) S/I/Rb (µg/ml) S/I/Rb (µg/ml) S/I/Rb
Ertapenem 4 R >32 R 32 R
Meropenem 4 R 4 R 16 R
Imipenem 4 R 8 R 8 R
Doripenem NT NT 8 R NT -
Ciprofloxacin 2 I NT - 0.5 S
Levofloxacin ≤1 S NT - NT -
Ampicillin >16 R NT - NT -
Amoxicillin-clavulanate >16/8 R NT - NT -
Aztreonam 16 I NT - NT -
Piperacillin-tazobactam 64 I NT - 32 I
Cefazolin >16 R NT - NT -
Cefuroxime >16 R NT - NT -
Cefoxitin >16 R NT - >64 R
Ceftriaxone NT - NT - >64 R
Cefotaxime >32 R NT - NT -
Ceftazidime >16 R NT - NT -
Cefepime >16 R NT - NT -
Gentamicin >8 R NT - NT -
Amikacin ≤8 S NT - 2 S
Tobramycin 8 I NT - NT -
Tigecycline ≤1 Sa NT - NT -
Fosfomycin >32 Ra NT - NT -
Colistin ≤2 Sa NT - NT -
S = Susceptible.
I = Intermediate.
R = Resistant.
a = Based on EUCAST breakpoints10  (no CLSI breakpoints were available).
b = Based on CLSI breakpoints.9
875
Scientific Letter
December 2011, Vol. 101, No. 12  SAMJ
aware of the possibility of a CRE being an NPE in patients who 
have epidemiological links to the Indian subcontinent, or other 
countries or hospitals where such isolates have emerged.14 In this 
case, there were no confirmed epidemiological links to the Indian 
sub-continent, therefore the validity of this epidemiological link 
requires further investigation. The patient had travelled widely within 
southern Africa and may have acquired the NPE from a neighbouring 
country. Heightened awareness and improved laboratory 
detection is mandatory and will give a clearer understanding of 
local epidemiology. CDC and HICPAC guidance for control of 
infections with carbapenem-resistant or carbapenemase-producing 
Enterobacteriaceae in acute care facilities recommends an aggressive 
infection control strategy encompassing laboratory testing, contact 
precautions and active surveillance.15 
Active surveillance is crucial to establishing the true prevalence of 
this resistance gene. The expression of NDM-1 in other significant 
hospital pathogens, such as A. baumannii, also requires consideration. 
From the perspective of laboratory detection, additional surveillance 
capacity is required given the characteristic carbapenem-resistant 
nature of such micro-organisms, which may otherwise allow NDM-1 
producers to go undetected. Phenotypic tests have limitations in 
detecting NDM-1; molecular confirmation is considered the ‘gold 
standard’ .8 Other infection prevention and control measures, such 
as environmental cleaning and selective decontamination of the 
gastrointestinal tract, may prove useful in halting dissemination and 
containing outbreaks of NPE. Acute healthcare institutions are urged 
to devise situation-specific infection control strategies for CRE, in 
an effort to stem the spread of these pathogens in South Africa. 
Vigilance and rapid action are our greatest weapons in the restricted 
arsenal currently available for combating this globally emerging 
resistance mechanism.
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